Globus Medical (GMED)vsJohnson & Johnson (JNJ)
GMED
Globus Medical
$80.26
-1.42%
HEALTHCARE · Cap: $10.45B
JNJ
Johnson & Johnson
$255.88
-3.66%
HEALTHCARE · Cap: $615.36B
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 3058% more annual revenue ($97.93B vs $3.10B). JNJ leads profitability with a 21.5% profit margin vs 18.9%. GMED appears more attractively valued with a PEG of 1.73. GMED earns a higher WallStSmart Score of 74/100 (B).
GMED
Strong Buy74
out of 100
Grade: B
JNJ
Buy57
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+35.9%
Fair Value
$137.63
Current Price
$80.26
$57.37 discount
Intrinsic value data unavailable for JNJ.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Earnings expanding 66.7% YoY
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Attractively priced relative to earnings
Reasonable price relative to book value
Strong operational efficiency at 21.3%
Mega-cap, among the largest globally
Every $100 of equity generates 25 in profit
Keeps 22 of every $100 in revenue as profit
Strong operational efficiency at 28.6%
Generating 3.4B in free cash flow
Areas to Watch
Expensive relative to growth rate
Moderate valuation
Expensive relative to growth rate
Earnings declined 1.0%
Comparative Analysis Report
WallStSmart ResearchBull Case : GMED
The strongest argument for GMED centers on EPS Growth, Debt/Equity, Altman Z-Score. Profitability is solid with margins at 18.9% and operating margin at 21.3%. Revenue growth of 27.0% demonstrates continued momentum.
Bull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 21.5% and operating margin at 28.6%.
Bear Case : GMED
The primary concerns for GMED are PEG Ratio.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, PEG Ratio, EPS Growth.
Key Dynamics to Monitor
GMED profiles as a growth stock while JNJ is a mature play — different risk/reward profiles.
GMED carries more volatility with a beta of 0.95 — expect wider price swings.
GMED is growing revenue faster at 27.0% — sustainability is the question.
JNJ generates stronger free cash flow (3.4B), providing more financial flexibility.
Bottom Line
GMED scores higher overall (74/100 vs 57/100), backed by strong 18.9% margins and 27.0% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Globus Medical
HEALTHCARE · MEDICAL DEVICES · USA
Globus Medical, Inc., a medical device company, develops and markets healthcare solutions for patients with musculoskeletal disorders. The company is headquartered in Audubon, Pennsylvania.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?